Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Zenshine Pharmaceuticals (Nanjing) Group / Equity Capital Markets

Zenshine Pharmaceuticals (Nanjing) Group (ZPN HK)

<ul>
<li>Zenshine, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CICC is the sole sponsor.</li>
<li>In this note, we look at the company's one late-stage core product, ZX-7101A/sebaloxavir marboxil.</li>
<li>We also look at the company's pre-IPO investors and management team.</li>
</ul>


Zenshine, a China-based biotech, is looking to raise at least USD 100 million via a Hong Kong listing. CICC is the sole sponsor.
In this note, we look at the company's one late-stage core product, ZX-7101A/sebaloxavir marboxil.
We also look at the company's pre-IPO investors and management team.


Zenshine (征祥医药) Pre-IPO: Differentiation Overstated in a Crowded PA CEN Class